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Abstract
Placenta-derived mesenchymal stem/stromal cells (PMSC) present several aspects that make 
them more attractive as cellular therapy than their counterparts from other tissues, such as 
MSC from bone marrow or adipose tissue in regenerative medicine. Placenta-derived MSC 
have been used to treat a variety of disorders, such as, cancer, liver and cardiac diseases, 
ulcers, bone repair, and neurological diseases. Placenta-derived MSC are relatively new 
types of MSC with specific immunomodulatory properties and whose mechanisms are still 
unknown. Placenta-derived MSC secrete some soluble factors that seem to be responsible 
for their therapeutic effects, i.e., they have paracrine effects. On the other hand, Placenta-
derived MSC can also serve as cellular vehicles and/or delivery systems for medications 
due to their migration capacity and their tropism for injury sites. Nanotechnology is an 
important field, which has undergone rapid development in recent years for the treatment 
of injured organs. Due to the special characteristics of placenta-derived MSC, the combina-
tion of these cells with nanotechnology will be a significant and highly promising field that 
will provide significant contributions in the regenerative medicine field in the near future.
Keywords: placenta, mesenchymal stromal cells, immunoregulation, regenerative 
medicine, nanotechnology, cancer, neurodegeneration, vascular, bone, cartilage, liver, 
urology, intestinal
1. Introduction
1.1. Structure and function of human placenta
Human placenta is an indispensable organ during pregnancy for supporting the develop-
ment of the fetus. The placenta is a unique organ since it is a multicellular barrier, in which 
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both maternal and fetal cells coexist. Placenta performs functions of metabolic exchange and 
endocrine regulation between two genetically distinct individuals, the mother and the fetus, 
while maintaining immunological tolerance between them [1, 2].
The term placenta derives from the latin and means “flat cake” because of its discoid shape. 
At the end of pregnancy, it is about 15–20 cm in diameter, 2–3 cm thick, and 500 g in weight, 
that is, 1/6 of the fetal weight.
The placenta is constituted by structures of fetal origin, such as, the placental disk, the fetal 
membranes, divided in amniotic and chorionic membranes, and the umbilical cord. The pla-
centa is also composed by a membrane of maternal origin termed the decidua that originates 
from the endometrium. The functional unit of the placenta is the chorionic villosity that forms 
the border between maternal and fetal blood during pregnancy (Figure 1).
1.2. Placenta development
Placenta development is a continuous process that starts during early embryological stages, 
even before gastrulation occurs. Four to five days after fecundation, the morula (solid mass of 
cells called blastomers) has reached the uterus. The appearance of a fluid-filled inner cavity 
marks the transition from morula to blastocyst and is accompanied by cellular differentiation: 
the surface cells become the trophoblast (giving rise to extraembryonic structures, including 
the placenta and the umbilical cord) and the inner cell mass gives rise to the embryo [3]. Just 
before the implantation into the endometrium, the internal cell mass or embryoblast, goes 
through important changes such as cellular reorganization that gives place to a top layer, the 
epiblast and a bottom layer named hypoblast or primitive endoderm. Some extraembryonic 
tissues such as the amnion derive from the epiblasts that delimit the amniotic cavity that hosts 
the embryo during pregnancy. Because of the increase in production of amniotic liquid during 
gestation, the amnion will expand, and merge with the trophoblast to give rise to the amnion-
chorionic membrane. Another of the earliest differentiation events in human embryogene-
sis takes place in the trophoblast with the development of the external syncytiotrophoblast 
Figure 1. First stage in the interaction between fetal and maternal blood circulation. The syncytiotrophoblast erodes 
maternal vessels.
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and the internal cytotrophoblast. The cytotrofoblast is constituted by highly proliferative 
mononucleated cells. Syncytiotrophoblast is formed by fusion of cytotrophoblastic cells and 
has high invasive capacity. This syncytium is responsible for the implantation or anchorage 
of the blastocyst within the uterine walls.
The lytic activity of the syncytiotrophoblast, which is responsible for the degradation of the 
matrix of the endometrium, reaches the uterine capillaries, eroding them. As a result of vascular 
damage, maternal blood comes out to the syncytiotrophoblast where it forms lacunae; this lacu-
nar stage is the first one toward a fetomaternal circulation. At the same time, the epithelial-like 
cells of the cytotrofoblast, which have continued proliferating, form accumulations that project 
toward the syncytiotrophoblast forming the chorionic villi that penetrate the decidua basalis 
[4]. These finger-like structures (cytotrophoblast covered with syncytiotrophoblast) are invaded 
by an extraembryonic mesoderm that, in the fourth week after fertilization, gives rise to blood 
vessels within each villi which makes possible the establishment of the interaction between the 
fetal circulation, in these embryo vessels, and the maternal blood contained in the trophoblastic 
lacunae (Figure 1). The different layers of the trophoblast (the cytotrophoblast and the syncy-
tiotrophoblast), the basal membranes of the fetal vessels, and the vascular endothelium of these 
vessels constitute the placenta barrier that regulates the metabolite exchange between both circu-
lations (fetal and maternal). It has been estimated that this exchange surface is about 5 m2 at week 
28 of gestation and reaches 10–11 m2 at term [5]. Moreover, this barrier undergoes a progressive 
thinning throughout pregnancy going from 10 microns at the beginning to 1 or 2 microns at the 
end of the gestation [6]. The umbilical cord connects placenta to the fetus. It is a narrow tube that 
contains two arteries and one vein to transport metabolites between mother and fetus.
1.3. Regenerative medicine and placenta
Regenerative medicine is an interdisciplinary field within translational medicine whose pur-
pose is to heal or replace damaged tissues or organs as a result of age, illness or trauma. It 
may involve the transplantation of stem cells that will repair the damaged tissue, stimulate 
the body’s own repair processes or serve as delivery-vehicles for therapeutic agents such as 
genes, cytokines, or therapeutic drugs.
Stem cells are unspecialized cells that have the capacity to renew themselves or differen-
tiate toward more specialized cells. The proliferation of stem cells is indispensable for the 
maintenance of the stemness niche. The differentiation is the process by which, under certain 
physiological or experimental conditions, unspecialized cells are induced to become tissue- or 
organ-specific cells. The differentiation potential of stem cells is essential during the develop-
ment of the embryo. In the adult, the main function of stem cells is the maintenance of the 
tissue homeostasis acting as an internal repair system.
Both embryonic and adult tissues are sources of stem cells with therapeutic potential. 
However, embryonic stem cells have some limitations in clinical practice, such as ethical con-
cerns, difficulty in obtaining, and tumorigenicity. Adult stem cells have been identified in 
many organs and tissues, including brain, bone marrow, peripheral blood, adipose tissue, 
skeletal muscle, skin, teeth, heart, gut, liver, and placenta. Though the number of stem cells 
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is very small in many adult tissues, their isolation involves several risks and, once removed 
from the body, the cells have a limited capacity of proliferation and differentiation, making 
the generation of large quantities of stem cells difficult.
The placenta is a reservoir of stem cells with several advantages. What makes placenta such 
an interesting tissue for regenerative medicine? Placenta is spontaneously expulsed at birth, 
making the use of invasive methods unnecessary as in the case of other sources of adult stem 
cells. It is considered a medical waste and there are no ethical concerns in its use, unlike using 
embryonic stem cells [7]. Placenta is a high-yielding source of stem cells compared to other 
sources such as bone marrow and adipose tissue where the cell recovery decreases with donor 
age [8]. Versatility and differentiation potential of placental cells is very high probably due 
to their primitive origin [9]. Furthermore, pregnancy is an example of “tolerated allograft” 
and placenta is the immunoregulatory organ at the maternal-fetal interface [10]. Placenta is 
an immunoprivileged organ, and cells isolated from placenta display low immunogenicity 
in vitro [11] and in vivo [12] when xenotransplanted in immunocompetent animals. The feasi-
bility of placental cells for allogeneic transplantation has been demonstrated [13].
In regenerative medicine, the effects of stem cells are not only restricted to cell or tissue res-
toration but also to transient paracrine actions. This paracrine action is related to factors pro-
duced and secreted by stem cells that will control the injury, modulate the immune responses, 
and promote self-repair in the surviving injured tissue [14]. Placenta plays a fundamental role 
in fetomaternal tolerance and this would explain why placenta-derived stem cells have an 
additional advantage over other stem cells in terms of immunomodulation [15].
Multiple mechanisms underlie maternal tolerance during pregnancy. Fetal and, in particular, 
placental tissues contribute to its immunoprivileged and immunoregulatory environment. 
Placental cells are characterized by the absence of MHC class II antigens that normally medi-
ate graft rejection [16]. Placental cells not only express a low level of the highly polymorphic 
forms of the MHC class I antigens but also express the nonclassical form HLA-G that may 
play a role in the suppression of immune responses and contribute to maternal-fetal tolerance 
[17, 18]. Furthermore, through the release of hormones [19], cytokines [20], and soluble forms 
of MHC antigens, placental cells deviate maternal immune responses toward immune toler-
ance. Therefore, the cells of the innate immunity of the mother acquire a suppressive profile 
characterized by a diminished production of pro-inflammatory cytokines. In addition, the 
B cells and many T cells disappear, leaving the regulatory T cells (Tregs) as the major T-cell 
subpopulation, with both, immune suppressive and anti-inflammatory characteristics [21].
1.4. Placenta-derived stem cells
Different populations of cells with features of stem/progenitor cells have been isolated from 
placenta: hematopoietic, epithelial, trophoblasts, and mesenchymal cells.
Placenta is a hematopoietic organ since it harbors a large pool of hematopoietic stem cells 
(HSC) that possess functional properties of true HSC. Placenta-derived HSC can differentiate 
into all types of mature blood cells and are able to sustain the hematopoiesis during the life of 
the embryo. Placental HSC activity declines toward the end of gestation, possibly reflecting 
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mobilization of placental HSC to the fetal liver and other developing hematopoietic organs 
within the embryo, such as thymus, spleen, and bone marrow [22].
The three layers of the placenta, such as the amnion, the chorion, and the decidua, are sources 
of stem cells. The amniotic layer is composed of a single-cell epithelial layer and a deeper 
mesodermal layer derived from the epiblast and hypoblast, respectively [23]. The chorion 
sheet is composed of the inner chorionic mesoderm similar to the mesenchymal region of the 
amnion and an outer layer of trophoblastic origin. The decidua, the uterine component of the 
placenta, is also a source of cells of mesodermal origin.
Amniotic epithelial cells (AEC) are very valuable stem cells for regenerative medicine. They 
have stem cell molecular markers such as OCT-4, Nanog, SOX-2, and Rex-1 (23). AEC do not 
have telomerase reverse transcriptase, show a stable karyotype, and do not originate tumors 
when injected. Amnion does not express MHC class II antigens, so AEC can elude the immune 
system. AEC can also modulate the immune system through an inhibition of the proliferation 
of T- and B-cells. In addition, AEC inhibit inflammation, as has seen in vitro [24].
Chorion trophoblastic cells (CTC) represent a mixed and still poorly characterized population 
of stem cells and there are no reliable methods to isolate them [25], and also, no consistent 
marking for identifying this population of cells [26].
Most of stem cells isolated from the placental tissues are cells of mesodermal origin and are 
named amnion mesenchymal stromal cells (AMSC), chorion mesenchymal stromal cells 
(CMSC), chorionic villi mesenchymal stromal cells (CV-MSC), and decidua mesenchymal 
stem cells (DMSC) [9, 27, 28] depending on the layer of origin. Inside the umbilical cord, 
there is a connective tissue that surrounds the umbilical vein and the two umbilical arter-
ies. This tissue, also known as Wharton’s jelly, is a rich source of mesenchymal stromal cells 
called umbilical cord mesenchymal stem cells (UC-MSC) [29]. They are all considered true 
mesenchymal stromal cells (MSC), as they meet the three minimal criteria proposed by the 
International Society for Cellular Therapy [30]. First, placenta-derived MSC exhibit plas-
tic adherence in culture. Second, they express a specific set of cell surface markers, such as 
CD105, CD73, and CD90, and do not express hematopoietic markers including CD34, CD45 
and CD14 or CD11b, CD79a or CD19, and HLA-DR. Third, they have the ability to differenti-
ate in vitro into different mesodermal cell lineages including adipocytes, chondrocytes, and 
osteoblasts. In addition, AMSC and CMSC are from fetal origin according to the first interna-
tional workshop on placenta-derived stem cells [31].
Cells with properties of mesenchymal stromal cells have also been isolated from the amni-
otic fluid (AF) which is used to perform the evaluation of karyotyping and prenatal diag-
nostic testing. AF is a source of MSC that could be used as autologous cellular therapy for 
perinatal disorders [32]. These AF-MSC can be easily isolated, have minimal ethical objec-
tions, high renewal activity, multiple differentiation capacity, and maintain genetic stability 
in culture [33].
In this chapter, we will refer to placenta-derived mesenchymal stromal cells as placenta mes-
enchymal stromal cells (PMSC) regardless of the placenta region where they were isolated.
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1.5. Placenta-derived mesenchymal stromal cells
Mesenchymal stromal cells (MSC) can be isolated from virtually all adult tissues in the body, 
although not always in large quantities. They are thought to be a precursor cell population 
capable of reconstituting all the cellular elements that comprise the supportive stromal tis-
sue in each organ [34]. First described in bone marrow as a subset of non-hematopoietic cells 
[35], they have become the paradigm cell in regenerative medicine. MSC are the most widely 
studied cell type in both preclinical and clinical trials. The advantages of MSC include ease 
of isolation and subsequent maintenance in culture, high expansion capacity, high plasticity, 
and tissue repair activity. The restorative activity of MSC is not necessarily by the replacement 
of dead or damaged cells, but also, by paracrine actions that mediate immune-regulation and 
promote cell growth and/or differentiation (Figure 2). Besides, MSC do not form teratomas 
after transplantation, ensuring safety to the host and, their low immunogenicity makes them 
suitable for allogeneic transplantation. Furthermore, these cells have the ability to migrate 
to inflammatory microenvironments [36] and tumors [12, 37], where they play an active role 
inducing many processes, such as angiogenesis and wound healing, mainly in a paracrine 
manner [38]. This feature provides an important therapeutic advantage to MSC since they can 
be injected via systemic infusion and can be used as vehicles for the delivery of drugs such as 
anticancer agents to the tumor site.
The use of placenta as a source of MSC has several advantages with respect to other adult 
MSC. Besides the ease of extraction of MSC from the placenta without invasive methods, 
the isolated MSC represent a more homogeneous and primitive population [9, 39]. The last 
feature is associated with a higher proliferative rate in culture compared to bone marrow 
MSC [40]. This fact makes it possible to achieve a greater number of cells in fewer passages 
Figure 2. PMSC mechanisms of action. PMSC can migrate, home, and differentiate into tissue specific cells to repair 
injured tissue, transport restorative genes and used as a cellular vehicles of therapeutic agents. PMSC also exert their 
actions through paracrine effects and have immunomodulatory properties.
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reducing the risk of ex vivo senescence influencing gene expression and resulting in aging 
phenotype [41, 42]. The senescent state needs to be taken into account for quality control 
of PMSC in cellular therapy. In addition, the clinical efficacy and safety of PMSC could be 
higher, compared to other sources of MSC, since PMSC are younger cells that have been 
exposed less time to harmful agents, such as reactive oxygen species (ROS), chemical and 
biological agents, and physical stressors [43]. Also, PMSC have a limited capacity to grow 
in culture related to low telomerase activity, which is also lost during proliferation, mak-
ing them a safe product to be used in regenerative medicine [9]. Moreover, PMSC could be 
advantageous with respect to migratory properties and homing capacities into damaged 
tissues. Homing of MSC is basically dependent on the release of chemoattractants by the 
injured tissue and the expression of chemokine receptors on the MSC membrane. For extrav-
asation into tissue, MSC have to attach to and migrate through the endothelium. Several 
integrins and other adhesion molecules are known to be expressed on MSC. Dependence 
on the VLA-4/VCAM-1 (very late antigen-4/vascular cell adhesion molecule-1) axis for MSC 
adherence to endothelial cells has been demonstrated [44]. PMSC have a higher expression 
of VLA-4 compared to bone marrow MSC suggesting that PMSC may have enhanced prop-
erties for homing to damaged tissue [45].
2. Therapeutic applications of placenta mesenchymal stromal cells 
(PMSC) in preclinical models
Stem cell therapies are expected to provide substantial benefits to patients suffering a wide 
range of pathologies. The plasticity and pleiotropic properties of PMSC that include immu-
nomodulation and inflammation control, angiogenesis, neuroprotection, and antiapoptosis, 
among others, have been widely evaluated at the preclinical level [9, 46, 47].
2.1. Use of placental mesenchymal stem/stromal cells in cardiovascular diseases
2.1.1. Myocardial infarction
Myocardial infarction (MI) is a major cause of death and disability worldwide. MI occurs 
when there is an interruption in blood flow to the heart muscle followed by heart ischemia. 
Since regeneration of heart muscle is virtually absent, damaged myocardium after infarct is 
replaced by scar tissue leading to reduced cardiac function. PMSC transplantation is a prom-
ising strategy to restore cardiac function and reduce myocardial fibrosis in MI due to their 
angiogenic and immunosuppressive properties.
PMSC have the potential to differentiate into cardiomyocytes, and exhibit spontaneous 
beating under in vitro conditions suggesting that they can therapeutically act in the car-
diac repair process [9, 48, 49]. Several groups have investigated the effects of PMSC when 
transplanted in animal models of MI. PMSC injected into rat hearts after the induction of a 
MI showed integration into cardiac tissues and in vivo transdifferentiation into cardiomyo-
cytes [48]. The CXCR4 chemokine receptor and its ligand, stromal cell-derived factor (SDF-1) 
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axis (CXCR4-SDF1) is the main pathway mediating migration of MSC toward injured tis-
sues. Since it has been shown that chemokine receptor type 4 (CXCR4) is greatly induced in 
PMSC by hypoxia, a high chemotactic response of PMSC to the ischemic microenvironment 
of the infarcted heart is expected [50]. Intravenous injection of PMSC in a rat model of infarct 
showed a sustained cardiac function over 32 weeks from injury [51]. Preconditioning PMSC 
by hyaluronan mixed ester of butyric and retinoic acid (HBR) potentiates their reparative 
capacity. Transplantation of preconditioned PMSC in pigs produced a significant reduction 
in scar size, higher myocardial perfusion and glucose uptake, enhanced capillary density, 
and decreased fibrous tissue [52]. The paracrine potential of conditioned medium (CM) of 
PMSC has also been evaluated. Injection of PMSC-CM limited infarct size and cardiomyo-
cyte apoptosis, while promoting capillary density in the infarct border area in a rat model of 
ischemia/reperfusion [53].
2.1.2. Critical limb ischemia
Critical limb ischemia (CLI) is the advanced stage of peripheral artery disease (PAD) with 
progressive stenosis, and ultimately the obstruction of peripheral arteries. The consequences 
of the markedly reduced blood flow to the lower limbs are pain at rest, nonhealing ulcers, 
and gangrene. The risk factors of PAD are advanced age, hyperlipidemia, hypertension, and 
mainly diabetes. Unfortunately, amputation, in many cases, is the only therapeutic option for 
CLI as blood capillaries cannot be corrected, and restenosis of vessels is produced.
Preclinical studies have reported benefits of cell therapy in neovascularization in several 
mouse models of hindlimb ischemia. PMSC have demonstrated pro-angiogenic effects when 
intramuscularly injected into the ischemic region of the affected limb, improving blood flow 
and promoting new vessel formation [54–56]. Similar results have been described in a diabetic 
nude rat model [57]. Moreover, CM from the PMSC also had pro-angiogenic action in a mouse 
hindlimb ischemic model, comparable to the PMSC transplanted group in the same study, 
revealing that PMSC action resulted primarily from a paracrine action of the angiogenic fac-
tors released from the PMSC [55]. However, in another study, cells were more efficacious than 
cell lysate in rescuing blood flow, probably indicating the importance of prolonged paracrine 
effect for maximal blood flow recovery [57].
2.1.3. Stroke
Stroke is an acute focal injury of the central nervous system (CNS) by a vascular cause, includ-
ing cerebral infarction, intracerebral hemorrhage (ICH), and subarachnoid hemorrhage 
(SAH), and is a major cause of disability and death worldwide. Thrombolysis is the most 
commonly used therapeutic approach although most patients fall outside of the clinical time 
window for effective treatment.
Experimental data show that stem cell therapy can limit neuronal degeneration and improve the 
functional outcome. The neuroprotective action of PMSC has been demonstrated in a rat model 
of stroke. Intravenous administration of PMSC, 4 hours after the injury, resulted in a signifi-
cant improvement of functional outcome and significant decrease of lesion volume, correlating 
with increased vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and 
brain-derived neurotrophic factor (BDNF) levels in the ischemic brain compared to controls [58].
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2.2. Use of placental mesenchymal stem/stromal cells in cancer
Cancer is one of the main problems in public health worldwide. Despite great progresses 
having been made in understanding the molecular basis of cancer, and the rapid advances 
in diagnosis, the efficacy of current treatment strategies is limited and mortality is still high. 
Stem cell-based treatments have been extensively explored for their possible potential to treat 
various cancers. Tumor microenvironment resembles a wound environment as tumors are 
considered as unhealed wounds [60]. Inflammatory and wound microenvironments induce 
migration of PMSC [36, 61]. Due to the characteristic of placenta-derived MSC, these cells 
represent an important tool for their use in anticancer therapies. First, PMSC can migrate 
and engraft into the tumor site and directly affect tumor biology through paracrine signaling. 
Second, PMSC could be used for the specific delivery of drugs to tumors thus reducing the 
doses administered and the side effects. Third, PMSC can also be genetically modified to give 
a stable expression of antitumor factors specifically in the tumor.
Placenta-derived MSC have an intrinsic tropism for sites of injury regardless of tissue or organ. 
Furthermore, it has been shown that PMSC and CM from PMSC are able to inhibit the pro-
liferation of several tumor cell lines [62]. Moreover, PMSC have an antitumor effect in vivo, 
inhibiting tumor progression when were intravenously injected in a rat model of mammary 
cancer [12]. Similarly, PMSC showed antitumor effects in vivo when previously expanded in 
the presence of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) [63] and 
when engineered to deliver growth factors to the tumor site, such as, pigment epithelium-
derived factor [64], or endostatin [65].
2.3. Use of placental mesenchymal stem/stromal cells in neurological diseases
Neurodegeneration involves a progressive and irreversible loss of neurons. Alzheimer’s, 
Parkinson’s, and multiple sclerosis are some of the more studied neurodegenerative syn-
dromes. The neuromuscular disorder amyotrophic lateral sclerosis (ALS) is a degenerative 
process caused by motor neuron loss. To date, there is no cure for these diseases. Cell therapy 
with stem cells arises as a therapeutic alternative based, either on the replacement of the lost 
neurons, or on a neuroprotective action through release of neurotrophic factors. PMSC are 
able to differentiate in vitro into several neural lineages, including neurons [9, 66], oligoden-
drocytes [66], glial cells [67], and dopaminergic neurons [68].
2.3.1. Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disease associated with a specific 
loss of dopaminergic neurons in the substantia nigra and depletion of dopamine levels in 
the striatum. The main therapeutic objective in PD is the recovery of dopaminergic neuro-
transmission in the striatum. Cellular replacement has been emerged as a suitable therapeutic 
strategy. First-trimester human PMSC differentiated to neural progenitors and transplanted 
into the striatum of a rat model of PD, underwent dopaminergic differentiation and showed 
an attenuation of the symptoms [69]. PD motor pathology is also accompanied by other dis-
abilities, such as, mood disorders, constipation, and hyposmia. It is expected that besides the 
regenerative effects of PMSC, the secretion of trophic factors, their anti-inflammatory and 
antiapoptotic effects, could also alleviate these nonmotor symptoms.
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2.3.2. Alzheimer’s disease
Alzheimer’s disease (AD) pathogenesis is characterized by a deposition of β-amyloid peptide 
and hyperphosphorylation of tau causing loss of the synaptic and neuronal activities and neu-
roinflammation. It has been demonstrated that PMSC, transplanted into an Alzheimer’s dis-
ease mouse model, modulated the inflammatory response. Moreover, mice injected with PMSC 
presented higher levels of β-amyloid degrading enzymes, reduced levels of pro-inflammatory 
cytokines, and increased levels of anti-inflammatory cytokines (TGF-β and IL-10). The effect 
of PMSC injection resulted in an improvement of memory function [70].
2.3.3. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by loss 
of nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, respiratory 
problems, and eventually, death. Multiple intravenous injections of PMSC in a mouse model 
of ALS, resulted in a protection of motor neurons from inflammatory effectors delaying func-
tional deterioration and increasing lifespan [71].
2.3.4. Multiple sclerosis
Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by 
demyelinated areas in the brain and spinal cord that heal forming a glial scar (sclerosis). 
It is believed that MS is caused by T cell-mediated autoimmune reaction against proteins 
of the myelin sheath inducing oligodendrocytes and neuronal loss. Most of therapies in 
MS patients target the immune system or the inflammatory process. Since the pathogenic 
process of MS can be divided into inflammatory and degenerative phases, PMSC-based cell 
therapy seems appropriate since it may be able to specifically regulate immune responses 
and also induce neuronal regeneration. The animal model that closely resembles the MS 
symptoms is the experimental autoimmune encephalomyelitis (EAE) in mice where the 
animals are injected with myelin antigens that initiate an immune response. Several pre-
clinical trials based on the treatment of EAE animals with PMSC have been published. 
Intracerebroventricular (ICV) transplantation of PMSC at day 5 (pre-symptomatology) 
or day 14 (at the beginning of the disease) after immunization, significantly reduced the 
severity of the disease and prolonged survival without delaying the onset of the disease 
[72]. Several intraperitoneal injections of PMSC in EAE mice delayed the onset of the symp-
toms and decreased disease incidence in the treated group respect to control, as well as 
inhibiting T cell proliferation and downregulating the production of pro-inflammatory 
factors while increasing the production of anti-inflammatory cytokines [73]. Likewise, ICV 
or intrathecal (ITH) injection of PMSC in EAE rats, also delayed the onset of motor symp-
toms, reduced inflammation, prevented axonal loss, and reduced disease severity [74].
2.4. Use of placental mesenchymal stem/stromal cells in bone and cartilage diseases
Bone regeneration is the physiological process of bone formation, which is involved in continu-
ous remodeling throughout adult life, and can be observed during bone healing after damage. 
However, there are large lesions created by traumatism, infection, tumor resection or skeletal 
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abnormalities in which physiological bone regeneration is not sufficient. There are also other 
conditions, such as osteoporosis, in which regeneration is compromised. PMSC have the poten-
tial to differentiate into osteogenic lineage, and seem to be an appropriate therapeutic option 
for bone regeneration. The use of 3D scaffolds that support cell differentiation and improve 
engraftment has become habitual in PMSC-mediated bone regeneration therapy. Several 
published studies confirm that PMSC have potent in vivo bone-forming capacity and may be 
worthwhile candidates for in vivo bone tissue repair. So, when PMSC were subcutaneously 
injected into severe combined immunodeficiency (SCID) mice with hydroxyapatite/tricalcium 
phosphate particles as a vehicle, new bone formation was found throughout all implants [75]. 
Another study showed that PMSC administered in combination with nanobiphasic calcium 
phosphate ceramics in a rat model of femur bone defects produced complete healing of the 
defect in 3 months without evidence of fibrosis [76].
Osteoarthritis (OA) is a degenerative process of the cartilage in joints. There is still no treat-
ment available to improve or reverse the degenerative process and current pharmacological 
treatments are only palliative. Given the potential of PMSC to differentiate into musculoskel-
etal lineages including bone and cartilage, MSC have been proposed as an optimal regenera-
tive cellular therapy for degenerative musculoskeletal conditions as OA. There are numerous 
data that support this hypothesis in preclinical models. PMSC embedded in a collagen I gel 
and transplanted in a rat model of femoral cartilage defect appeared to cover the tissue defects 
with soft tissue positive for toluidine blue suggesting in vivo differentiation of transplanted 
cells [77]. Also PMSC grown on silk fibroin and transplanted into the knee in rabbits with 
knee osteochondral defects resulted in newly created hyaline cartilage without inflammatory 
response [78]. Similarly, PMSC seeded onto poly lactic-co-glycolic acid (PLGA) and precondi-
tioned in chondrogenic medium were well tolerated and found in the reparative tissue of OA 
rabbit knees 8 weeks after transplantation [79].
2.5. Use of placental mesenchymal stem/stromal cells in liver diseases
Cirrhosis is the common end-stage of most of the injuries affecting the liver such as virus 
infections, chronic alcoholism, metabolic diseases, or acute liver failure. A scar is formed by 
extracellular matrix, making the normal function of the liver difficult. Cirrhosis is an irrevers-
ible state that can become life-threatening and, frequently, liver transplantation is the only 
alternative for healing. Donor shortage and continuous need for immunosuppression are the 
main limitations to liver transplant and cell transplantation appears as a suitable alternative. 
In addition to fetal and adult hepatocytes, stem cells are considered for cell transplantation. 
PMSC can be helpful since their potential capacity to differentiate to hepatic-like cells and 
form functional three-dimensional structures have been reported [80].
Transplanted into animal models of disease, PMSC induced a significant reduction of fibro-
sis and of serum levels of transaminases. Liver regeneration has been proposed to be pro-
moted by the induction of autophagy process [81], stimulation of liver cell proliferation [82], 
decreased apoptosis, and suppression of stellate cells activation [83]. Although no evidence 
of differentiation of the transplanted cells into hepatocytes was reported in a CCl4-induced 
fibrosis rat model [82], in other models, PMSC engraftment and expression of human albumin 
and α-fetoprotein have been reported [83–85].
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2.6. Use of placental mesenchymal stem/stromal cells in intestinal inflammatory 
diseases
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic conditions caused by a sustained 
inflammation of the intestinal epithelium that ends in tissue destruction throughout the gas-
trointestinal tract. It is believed that these disorders are the result of an abnormal host immune 
response to intraluminal antigens in genetically predisposed individuals. Several genetic vari-
ants of nucleotide-binding oligomerization domain 2 (NOD2) are associated with the develop-
ment of Crohn’s disease [86]. Both pathologies have a major impact on the quality of life and 
there is no curative treatment. Furthermore, many patients are not responsive to current therapy.
Intraperitoneal administration of conditioned medium from PMSC ameliorated clinical param-
eters in a mouse model of dextran sulfate sodium (DSS)-induced colitis [87]. Intraperitoneal 
injection of PMSC also prevented the loss of body weight and decreased the mortality of mice. 
These benefits were greater when NOD2-activated PMSC were used [88].
2.7. Use of placental mesenchymal stem/stromal cells in urological diseases
Stress urinary incontinence (SUI) is a widespread disorder, commonly associated with child-
birth, with a detrimental impact on the quality of life. SUI triggers a weakening of muscles 
and ligaments causing involuntary leakage of urine during physical activity, sneezing, or 
coughing. Surgical intervention to place a tissue sling that provides support to the urethra is 
the usual therapeutic action.
Animal models of SUI have been employed to prove the benefits of cell therapy in this pathol-
ogy. Periurethral injection of myogenic differentiated PMSC in SUI mice restored the urethral 
sphincter to apparently normal histology and function [89].
3. Use of placenta mesenchymal stem/stromal cells (PMSC) and 
nanotechnology for tissue regeneration
The goal of cell-based regenerative medicine is to repair, replace, or regenerate cells, tissues, 
or organs when damaged. However, there are still some unresolved issues such as engraft-
ment of transplanted cells onto the injured tissue and the survival for the time needed to 
repair the damage. Nanotechnology can be very helpful since nanomaterials can be used as 
scaffolds to improve the engraftment of stem cells onto the damaged tissue. In addition, the 
use of nanoparticles (NPs) for gene/drug delivery can complement the therapeutic benefits of 
transplanted stem cells, and allow the tracking of the cells inside the body [90].
Several reports described the therapeutic application of PMSC combined with biomaterials. 
PMSC proliferation and differentiation into myocardial and neuronal cells improved when the 
cells were grown on top of gold-coated collagen nanofibers (GCNFs) [91]. The peptide hydro-
gel PuraMatrix® (PM; 3-D Matrix, Ltd) was used to support PMSC in rat models of both acute 
MI and post-MI ischemic cardiomyopathy. The peptide hydrogel and the PMSC create a film 
to coat the heart. The epicardial “coating” method has advantages with respect to intramyo-
cardial injection such as higher survival of the transplanted cells and lower complications [92].
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In bone regenerative medicine, the RKKP glass ceramic has been proposed as a biocompatible 
support for PMSC. RKKP exhibits a higher osteointegration rate compared to other ceramic 
materials mainly in osteopenic bone. Additionally, the biology of PMSC is not affected when 
grown over this support while maintaining their osteogenic potential [93] PMSC seeded over 
poly-L-lactic acid (PLLA) nanofibrous scaffolds and subjected to osteogenic conditions have 
been successfully grafted in a rabbit model of sternal defect closure [94].
Some systems have shown suitable behaviors as recipients of PMSC for cartilage regeneration. 
Collagen sponge allowed the formation of a cartilage-like tissue both, in vitro and in vivo, 
under chondrogenic-inducing conditions [95]. Similarly, PMSC embedded in alginate incor-
porating nanosized calcium-deficient hydroxyapatite (nCDHA) and/or a recombinant protein 
containing arginine-glycine-aspartate (RGD) and seeded over poly(D,L-lactide-co-glycolide) 
(PLGA) gave rise to cartilage formation [96].
The use of nanoparticles for gene/drug delivery can significantly contribute to the advance of 
regenerative medicine. The use of stem cells as carriers of NPs containing biologically active 
molecules (e.g., pro-survival, anti-inflammatory) or chemicals such as anticancer drugs is very 
promising. PMSC have been employed as a platform to load mesoporous silica nanoparticles. 
NP loading did not affect the chemotactic ability of PMSC toward tumors in vitro and in vivo. 
When carrying doxorubicin-loaded NP, PMSC promoted breast cancer cells death in a co-
culture system [97]. In a proof of concept, ultrasound-responsive NPs loaded with antitumor 
drugs were transported to tumor tissues by PMSC, and the cargo was released by NPs only 
after ultrasound application [98].
In vivo monitoring of cells, after transplant, is needed and NP-based probes are useful for 
this purpose. They offer the possibility of tracking the bio-distribution and engraftment of 
cells into the body with minimally invasive techniques. However these probes have to ensure 
minimal changes in cell phenotype [97]. PMSC have been efficiently labeled with albumin-
conjugated fluorescent nanodiamonds (FNDs) [99], with silica-coated magnetic nanoparti-
cles incorporating rhodamine B isothiocyanate, MNPs@SiO2(RITC) [100], with rhodamine B 
labeled mesoporous silica nanoparticles [98] and with human serum albumin coated iron 
oxide nanoparticles (HSA-IONPs) [101] without any detrimental effect.
4. Therapeutic applications of placenta mesenchymal stem/stromal 
cells (PMSC) in clinical trials
Based on the benefits produced by transplanted PMSC in different animal models resembling 
human diseases, some clinical studies have been carried out and there are also an increas-
ing number of ongoing clinical trials. The web pages http://www.clinicaltrialsregister.eu and 
http://www.clinicaltrial.gov offer up-to-date information on clinical trials giving current sta-
tus. There are a good number of completed trials of which no results have yet been published. 
Other completed studies and clinical trials have published reports with the results obtained 
demonstrating the safety of the use of PMSC. In general, therapeutic benefits have been found.
Intracoronary infusion of UC-MSC in MI patients resulted in safe and significantly improved 
myocardial viability and the perfusion within the infarcted area. Improvement in some 
Human Placenta-Derived Mesenchymal Stromal Cells: A Review from Basic Research to Clinical Applications
http://dx.doi.org/10.5772/intechopen.76718
239
parameters such as the increase in the left ventricular ejection fraction (LVEF) and decreases 
in end-diastolic volumes and LV end-systolic volumes were observed up to 18 months after 
treatment [102]. RIMECARD is a phase I/II clinical trial that has demonstrated the safety and 
efficacy of the intravenous infusion of UC-MSC in patients with chronic heart failure and 
reduced ejection fraction. Improvements in left ventricular function, functional status, and the 
quality of life were observed in treated subjects [103].
Cell therapy has been introduced as a new therapeutic attempt to restore blood flow and 
attenuate ischemia promoting collateral vessel formation in CLI. In January 2017, a Phase III 
study of PLX-PAD cells1 in the treatment of critical limb ischemia (CLI) has been cleared by 
the U.S. Food and Drug Administration (FDA). Data from previous studies have shown that 
by increasing tissue perfusion, PMSC may improve the healing of wounds in CLI patients, 
and could allow for significant delays in events of amputation and death.
Safety and efficacy of UC-MSC infusion in patients with decompensated liver cirrhosis have 
been reported in a 1-year follow-up study. There were no significant side effects or complica-
tions and there was a significant reduction in the volume of ascites and improvement in liver 
function, as indicated by the increase of serum albumin levels and a decrease in total serum 
bilirubin levels [104].
Therapeutic effects of PMSC transplantation in MS patients have been evaluated in dif-
ferent studies. Intravenous infusion of UC-MSC appears to be safe and well tolerated 
in patients with MS, and the overall symptoms of treated patients remained stable or 
improved compared to the control group [105]. In another clinical trial, patients with 
relapsing-remitting MS or with secondary progressive MS randomly received PMSC 
(PDA-001)2 and most treated subjects had stable or decreasing Expanded Disability 
Status Scale scores [106].
OA affecting the hip can mean, in many cases, the need for a total hip replacement (THR). 
A frequent side effect of THR is a gluteus medius injury. PMSC administered directly to the 
injured muscle during surgery have demonstrated their safety and efficacy inducing a greater 
increase in the gluteus medius muscle strength than placebo, and a significant improvement 
in muscle volume based on MRI. EudraCT Number: 2011-003934-16.
Safety of the intravenous administration of PMSC (PDA001) to moderate-to-severe Crohn’s 
disease patients unresponsive to other therapies has been demonstrated and some remission 
rates of the disease have been reported [107]. Likewise, in a randomized controlled clinical 
trial, intravenous injection of PMSC patient condition improved significantly allowing a sig-
nificant reduction in steroid dosage. Additionally, several patients with anal fistula showed 
remarkable improvement [108].
1 PLX-PAD – Placenta eXpanded adherent stromal cells produced by PluriStem Ltd. PLX-PAD cells are derived from the 
decidua of human placenta and are expanded using the company’s 3D proprietary technology.
2 PDA-001 (previously cenplacel-L) is a placenta adherent cells-based therapy developed by Celgene Cellular Therapeutics 
(CCT, a subsidiary of Celgene Corporation) to treat autoimmune diseases. It is administered as an intravenous injection.
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5. Conclusions
PMSC are promising candidates for use in regenerative medicine in humans. Cell therapy 
using PMSC is based mostly on three important characteristics of these types of cells: (i) 
their inherent reparative capacities or by secretion of paracrine factors; (ii) their homing and 
engraftment abilities; and (iii) their immune modulation capacities. However, clinical use of 
PMSC is still in its infancy and most of the trials are, to date, under development. Most studies 
of cellular therapy have been realized with autologous cells. Nevertheless, the use of patient’s 
own cells has several limitations. First, there is a time-limiting factor as the expansion and 
quality control of autologous cells may require several weeks. Furthermore, the cells can show 
less potency due to inherent aging aspects and, even, certain characteristics of the subject may 
render autologous transplantation unfeasible as occurs in the case of elderly patients and 
those having a specific systemic disease such as diabetes. In contrast, allogeneic MSC have 
the potential to be mass-produced rapidly so they can be readily available and administered 
immediately. They can be obtained under more standardized and strictly validated condi-
tions and probably reduce costs. To date, published data regarding reliability of treatment 
with PMSC indicate that the use of PMSC is safe and therefore there are already products 
“off-the-shelf.” Although most clinical trials are ongoing or have no published results, there 
are some favorable data regarding to the efficacy of treatments with PMSC.
Stem cell nanomedicine is a very promising field that at the preclinical level has yielded very 
encouraging results. Treatment of certain pathologies can benefit from the use of scaffolds that 
provide a three-dimensional structure to give support to the cells, promoting their adhesion 
and growth, so definitely improving the engraftment and therefore the therapeutic results. 
Besides the use of cells as carriers of nanoparticles to deliver drugs inside the injured tissue 
and, even more, the possibility of stimulus-controlled release of the drug appears exciting.
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